BioCentury
BioCentury
YouTubeLinkedInXRSS
ARTICLE | Distillery Therapeutics

Inhibition of ATP1A2 for tauopathies including Alzheimer’s

By biocentury staff
April 1, 2022 5:04 AM UTC

DISEASE CATEGORY: Neurology

INDICATION: Alzheimer’s disease...

BCIQ Company Profiles

Washington University School of Medicine in St. Louis

BCIQ Target Profiles

ATPase Na+/K+ transporting alpha 2 polypeptide (ATP1A2)

BCIQ Company Profiles

Washington University School of Medicine in St. Louis

BCIQ Target Profiles

ATPase Na+/K+ transporting alpha 2 polypeptide (ATP1A2)

About BioCentury

Privacy & Legal

Contact

About BioCentury

Company Overview
Management
Editorial & Research
Scientific Advisory Board

Privacy & Legal

User Agreement
Terms of Use
Privacy Policy
Use of Images & Market Data
Reprints & Permissions

Contact

Contact Us
Advertising & Sponsorship
Customer Resource Center
Career Opportunities
Forgot Password
YouTubeLinkedInXRSS
BioCentury
© 2025 BioCentury Inc. All Rights Reserved.
Copyright © 2025 BioCentury Inc. All Rights Reserved.
YouTubeLinkedInXRSS